Case series reports severe immune-mediated colitis in ocrelizumab-treated individuals, prompting updated safety warnings on drug prescribing information.
This case series highlights ocrelizumab induced immune-mediated colitis that can be clinically severe and potentially life-threatening. Based on the findings of this review, the ocrelizumab Prescribing Information was amended to include immune-mediated colitis in the Warnings and Precautions section.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: